BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1472380)

  • 41. The antisense homology box: a new motif within proteins that encodes biologically active peptides.
    Baranyi L; Campbell W; Ohshima K; Fujimoto S; Boros M; Okada H
    Nat Med; 1995 Sep; 1(9):894-901. PubMed ID: 7585214
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The statistical significance of selected sense-antisense peptide interactions.
    Illingworth CJ; Chintipalli SV; Serapian SA; Miller AD; Veverka V; Carr MD; Reynolds CA
    J Comput Chem; 2012 Jun; 33(16):1440-7. PubMed ID: 22488506
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antisense peptides to the 43-57 region of acylphosphatase and to the 46-60 region of two isoenzymes of a low-M(r) phosphotyrosine protein phosphatase do not interact with the corresponding proteins.
    Stefani M; Bucciantini M; Taddei N; Mincione G; Manao G; Ramponi G
    Biotechnol Appl Biochem; 1994 Oct; 20(2):241-9. PubMed ID: 7986380
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Purification of recombinant human interferon-beta by immobilized antisense peptides.
    Scapol L; Rappuoli P; Viscomi GC
    J Chromatogr; 1992 May; 600(2):235-42. PubMed ID: 1400848
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Complementary peptides as interactive sites for protein binding.
    Bost KL; Blalock JE
    Viral Immunol; 1989; 2(4):229-38. PubMed ID: 2482027
    [TBL] [Abstract][Full Text] [Related]  

  • 46. On antisense peptides: the parathyroid hormone as an experimental example and a critical theoretical view.
    Rasmussen UB; Hesch RD
    Biochem Biophys Res Commun; 1987 Dec; 149(3):930-8. PubMed ID: 2447888
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Complementarity of peptides specified by 'sense' and 'antisense' strands of DNA.
    Blalock JE
    Trends Biotechnol; 1990 Jun; 8(6):140-4. PubMed ID: 1369993
    [No Abstract]   [Full Text] [Related]  

  • 48. A simple three-step method for design and affinity testing of new antisense peptides: an example of erythropoietin.
    Štambuk N; Manojlović Z; Turčić P; Martinić R; Konjevoda P; Weitner T; Wardega P; Gabričević M
    Int J Mol Sci; 2014 May; 15(6):9209-23. PubMed ID: 24865486
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular Recognition Theory of the complementary (antisense) peptide interactions.
    Stambuk N; Konjevoda P; Boban-Blagaić A; Pokrić B
    Theory Biosci; 2005 Apr; 123(4):265-75. PubMed ID: 18202868
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antisense technology: biological utility and practical considerations.
    Neckers L; Whitesell L
    Am J Physiol; 1993 Jul; 265(1 Pt 1):L1-12. PubMed ID: 8393300
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Making sense of antisense.
    Yacyshyn BR; Shanahan WR
    Can J Gastroenterol; 1999 Nov; 13(9):745-51. PubMed ID: 10633827
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antisense strategies in cell and developmental biology.
    Colman A
    J Cell Sci; 1990 Nov; 97 ( Pt 3)():399-409. PubMed ID: 2074263
    [No Abstract]   [Full Text] [Related]  

  • 53. Bioaffinity chromatography: synergy between interactive chromatography and molecular recognition for the separation and analysis of macromolecules.
    Chaiken IM
    J Chromatogr; 1989 Mar; 488(1):145-60. PubMed ID: 2715281
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sense, antisense, nonsense: where's the right way?
    Bricca G
    J Mol Med (Berl); 1995 Aug; 73(8):417-9. PubMed ID: 8528744
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diversification of antisense research and development: review of the Ringberg meeting, April 1994. Mechanisms of antisense-mediated gene silencing.
    Hawkins JW; Nellen W
    Antisense Res Dev; 1994; 4(2):127-9. PubMed ID: 7950300
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The new genetic medicines.
    Cohen JS; Hogan ME
    Sci Am; 1994 Dec; 271(6):76-82. PubMed ID: 7809596
    [No Abstract]   [Full Text] [Related]  

  • 57. Peptide design.
    Glass DB
    Nature; 1994 Aug; 370(6488):334. PubMed ID: 8047137
    [No Abstract]   [Full Text] [Related]  

  • 58. Antisense technology--commercialization of new biotherapeutics.
    Conway BJ; Chrisey LA
    Antisense Res Dev; 1991; 1(2):195-9. PubMed ID: 1841661
    [No Abstract]   [Full Text] [Related]  

  • 59. Progress in evaluation of the potential of antisense technology.
    Crooke ST
    Antisense Res Dev; 1994; 4(3):145-6. PubMed ID: 7849484
    [No Abstract]   [Full Text] [Related]  

  • 60. Making sense of asthma.
    Richardson PJ
    Expert Opin Investig Drugs; 1997 Sep; 6(9):1143-7. PubMed ID: 15991888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.